Updates in Hepatitis B Virus: Screening, Monitoring, and Current and Emerging Therapies
SmartMobile(TM)Premiere Date: Friday, June 15, 2018
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, June 15, 2019
Note: Credit Is No Longer Available
|Amy Shen Tang, MD
Hepatitis B Program Director
Charles B. Wang Community Health Center
New York, NY
The Centers for Disease Control and Prevention (CDC) released the first Action Plan for the Prevention Care & Treatment of Viral Hepatitis in 2011, but despite early successes, progress in reducing the number of hepatitis B virus (HBV) infections has stalled, and HBV-related deaths have increased. The National Strategy for the Elimination of Hepatitis B and C Phase 2 Report was released in March 2017 and indicated that better attention to prevention, screening, and treatment of hepatitis B and C could eliminate the burden of these diseases and prevent nearly 90,000 deaths by 2030.
These data warranted a new action plan to address challenges and opportunities in the efforts against viral hepatitis, as there have been missed opportunities for clinicians to prevent transmission, diagnose individuals, treat HBV, and reduce the number of deaths.
The National Viral Hepatitis Action Plan 2017-2020 presents key goals and strategies for these issues, and this CME Outfitters mobile case series is designed to help primary care and internal medicine clinicians move toward achieving the Action Plan goals by testing knowledge, confidence, and performance in optimizing treatment for patients with HBV.
At the end of this CE activity, participants should be able to:
- Examine ACP and AASLD guidance updates on hepatitis B virus (HBV) screening, treatment, and monitoring.
- Remain abreast of emerging treatments aimed at achieving a functional cure for HBV.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, internists, gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Amy Shen Tang, MD has no disclosures to report.
Kashemi Rorie, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Shari Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).